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(95% confidence interval, CI = 38–55; algorithm) and 42% 
(95% CI = 29–54; individual). Clinical response was paralleled 
by improved quality of life in both groups. Physicians ad-
hered to the algorithm option in 93% of their treatment deci-
sions.  Conclusion: Treatment following an evidence-based 
algorithm is an effective and applicable concept for the 
management of AE but does not show clear advantages 
compared to individualised treatment in a dermatological 
setting.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Atopic eczema (AE, synonymous with atopic derma-
titis) is a multifactorial, itchy, inflammatory skin disease 
that affects up to 20% of children and 2–4% of adults  [1, 
2] . Even patients with clinically mild disease frequently 
report substantial problems in everyday life  [3] . AE im-
poses a high economic burden with both total cost and 
out-of-pocket expenses similar to those of asthma  [4] . 
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 Abstract 
 Background: Evidence-based treatment algorithms, suc-
cessfully established for asthma, are missing for atopic ec-
zema (AE).  Objectives: To investigate whether treatment ac-
cording to an evidence-based algorithm is an effective and 
applicable concept for the management of AE.  Methods: 
Based on a systematic literature review, we developed an 
evidence-based severity-score-oriented treatment algo-
rithm for AE and compared its effectiveness to that of an in-
dividualised symptom-oriented treatment (individual thera-
py) in a randomised controlled trial. Sixty-three participants 
were randomised to algorithm (n = 32) or individual therapy 
(n = 31) and treated accordingly for 12 months. Study end 
points included difference between baseline SCORAD and 
mean SCORAD under treatment (primary end point), quality 
of life and treatment utilisation. Analysis was by intention to 
treat (registration: ClinicalTrials.gov:NCT00148746).  Results: 
 No statistically significant differences in clinical or subjective 
response were observed between groups. Treatment fol-
lowing the algorithm and individual treatment both effec-
tively controlled AE. Mean SCORAD reductions were 47% 
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Currently not curable, the symptomatic treatment in-
cludes topical anti-inflammatory substances such as top-
ical corticosteroids and topical calcineurin inhibitors, 
phototherapy, and systemic immunosuppressive agents 
such as oral corticosteroids, cyclosporine and azathio-
prine  [5] . Only few head-to-head trials have been pub-
lished for AE  [5–7] . Drugs assessed in different placebo-
controlled trials are not objectively comparable because 
of heterogeneous inclusion criteria and outcomes used 
 [8] . Although some of the published treatment guidelines 
for AE have been developed using evidence-based meth-
ods, they have not been validated using methods of evi-
dence-based medicine, i.e. by applying them in the set-
ting of a randomised controlled trial (RCT)  [9–11] .
 For other chronic conditions such as allergic asthma, 
chronic pain or depression, it has been shown that sever-
ity-score-based treatment algorithms improve disease 
management and control  [12–14] . Recent studies suggest 
that in children with AE early and sustained disease con-
trol may decrease the risk of subsequent atopic diseases 
including allergic rhinitis and asthma  [15, 16] . Further-
more, in both children and adults effective control of in-
flammation seems to decrease the risk of persistent dis-
ease and may thus modify the course of AE  [17, 18] . A 
validated treatment algorithm may therefore help to im-
prove medical care of patients with AE.
 We developed a standardised, evidence-based, time- 
and severity-score-dependent treatment algorithm for 
children and adults with moderate-to-severe AE (‘algo-
rithm’) that gives explicit recommendations for objec-
tively defined disease states and tested its effectiveness 
against individualised symptom-oriented treatment (‘in-
dividual’) in a pragmatic RCT.
 Methods 
 Development of the Time- and Severity Score-Oriented 
Treatment Algorithm 
 A comprehensive literature review was conducted using mul-
tiple overlapping search strategies to develop an evidence-based 
treatment algorithm for moderate-to-severe AE that gives exact 
recommendations including name of drug, frequency and dura-
tion to be used depending on objective disease severity, prior 
course of disease and patient age. We searched Medline and the 
Cochrane central register of controlled trials (both from incep-
tion until December 2003) using different combinations of the 
medical subject (MeSH) terms ‘atopic dermatitis’, ‘randomised 
controlled trial’, ‘review’, ‘guideline’, ‘consensus’ and text key 
words including the names of all drugs approved for AE. To iden-
tify additional articles with potential information we also re-
viewed the bibliographies of selected key articles  [6, 9, 19–21] . Fi-
nally, we reviewed the summary of product characteristics of all 
treatment options for moderate-to-severe AE that we intended to 
include in the treatment algorithm based on our literature 
search.
 We only identified few head-to-head RCTs  [22–28] . The inclu-
sion criteria and outcomes used in the placebo-controlled trials 
are too heterogeneous to objectively compare interventions across 
trials  [5, 6, 29, 30] . The treatment guidelines identified suggest 
multiple drug classes (e.g. topical corticosteroids, topical calci-
neurin inhibitors) for not objectively defined disease states (e.g. 
severe refractory disease, acute exacerbation, persistent disease, 
flare). However, guidelines do neither specify exactly which drug 
to administer for how long in a certain disease state nor do they 
objectively define disease states by explicit criteria (e.g. disease 
severity score, quantitative definition of ‘persistent disease’)
 [9, 11] .
 Therefore, it was not possible to base our study on an algo-
rithm that is definitely the most effective according to the pub-
lished evidence. Our goal was to develop an algorithm that com-
bines the evidence of RCTs with the regulatory guidelines (sum-
mary of product characteristics) of the drugs used and thus to 
include everyday clinical practice into the setting of a clinical
trial.
 The treatment algorithm was drafted by J.S., revised by M.M. 
and K.S., and finalised by consensus of all authors.
 The final algorithm consists of two steps: (1)  stepwise treat-
ment escalation to induce response ( fig. 1 a) ; (2)  management of 
flares depending on previously effective treatment ( fig. 1 b). 
 Study Design and Participants 
 We performed a pragmatic, investigator-initiated, parallel-
group, randomised, patient-blinded, active controlled clinical tri-
al to assess the effectiveness and safety of the time- and severity-
score-dependent treatment algorithm (‘algorithm’) compared to 
individualised symptom-oriented treatment (‘individual’). The 
study protocol was approved by the local ethics committee. All 
study subjects gave written informed consent before trial partici-
pation. No external sponsor was involved in this investigator-ini-
tiated study. The study was registered at ClinicalTrials.gov (iden-
tifier: NCT00148746).
 The study was conducted at the outpatient clinic of the De-
partment of Dermatology, Medical Faculty Carl Gustav Carus, 
University of Technology, Dresden, Germany. Between June 2004 
and September 2005, 64 patients aged 2 years and older with AE 
 [31] , who had at least moderate disease activity with a SCORAD 
 [32] (scoring atopic dermatitis) score  6 20, were enrolled. Patients 
with prior malignant disease, women without adequate contra-
ception and pregnant/nursing women were not eligible. There 
was no wash-out phase for any drugs administered prior to inclu-
sion. Participants were mainly recruited by referrals from derma-
tologists and paediatricians, and by information about this study 
in the local press.
 Six dermatologists were randomly allocated at a ratio of 1: 1 by 
drawing identically looking lots to treat patients either strictly fol-
lowing the algorithm or to perform individualised symptom-ori-
ented treatment (individual). During the screening visit, patients 
underwent central randomisation with the use of a permutated-
block randomisation list (block length 4), with equal allocation to 
the algorithm and individual groups. The allocation sequence 
was generated by SPSS (version 11.5.1, SPSS Inc.). Stratification by 
disease severity (SCORAD 20–50 vs. SCORAD  1 50) and by par-
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ticipant age (2–15 vs.  6 16 years) was used to minimise baseline 
differences in these potential confounders. The allocation se-
quence was concealed to all investigators until interventions were 
assigned. Throughout the study the participants did not know 
which treatment had been allocated.
 Study Procedures 
 In both study groups patients were treated exclusively with 
drugs approved for AE. All drugs were supplied by prescription. 
Additional use of emollients was permitted, and patients on anti-
histamines at baseline were allowed to continue on the same dose 
throughout the study. Physicians allocated to follow the algo-
rithm were only allowed to violate the treatment scheme ( fig. 1 ) if 
a proposed drug was contra-indicated. At the end of the study, one 
investigator (J.S.) double-checked the treatments prescribed to 
the participants allocated to the algorithm group and recorded all 
violations against the treatment scheme.
 Study visits were scheduled every 4 weeks ( 8 1 week) for a total 
of 1 year (13 visits after baseline). At each visit we assessed: current 
objective disease activity by means of the SCORAD, current global 
disease severity independently assessed by the physician (investiga-
tor global assessment, IGA  [33] ) and by the patient (patient global 
assessment, PGA), and the current impact of AE on everyday life 
using the children  [34] or adult  [35] version of the dermatology life 
quality index (DLQI; children: 5–16 years; adults: 17 years or older). 
Quality of life was not assessed in children aged  ! 5 years.
 The primary measure of effectiveness was the difference be-
tween baseline SCORAD and mean SCORAD under treatment.
All other variables were defined as secondary end points. The
SCORAD is the most widely used and most extensively validated 
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 Fig. 1. Time- and severity-score-depen-
dent treatment algorithm for moderate-
to-severe AE with stepwise treatment es-
calation to induce response ( a ) and man-
agement of flares depending on previously 
effective treatment ( b ). Moderate AE: 
baseline SCORAD 20–50; severe AE: base-
line SCORAD  1 50. Tacrolimus: age 2–15 
years, 0.03%; 16 years or older, 0.1%. Topi-
cal steroids: face, hydrocortisone 1.0%; 
body, with SCORAD  1 50 mometasone fu-
roate 0.1%, with SCORAD  ̂  50 predni-
carbate 0.25%; dose: week 1 b.i.d., week 
2–3 once a day, week 4 every other day. 
Prednisolone: days 1–3, 1.0 mg/kg BW; 
days 4–7, 0.5 mg/kg BW; days 8–10, 0.25 
mg/kg BW; days 11–14, 0.1 mg/kg BW. 
Topical calcineurin inhibitors (TCI): pi-
mecrolimus b.i.d. (face); tacrolimus b.i.d. 
(body) until 1 week after remission (de-
fined as SCORAD  ! 8); repeated applica-
tion as soon as first clinical signs or symp-
toms of eczema appear. Response defined 
as SCORAD 50, i.e. relative reduction 
compared to baseline SCORAD  6 50%. 
Cyclosporine: initial dose, 5 mg/kg BW; 
stepwise reduction to minimum effective 
dose; minimum treatment duration 6 
weeks (in the absence of adverse reactions); 
treatment may be continued up to 1 year. 
Flare: increase in SCORAD to a score 
 1 50% of baseline SCORAD after prior re-
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severity index for AE  [8] . The SCORAD combines an assessment 
of disease extent using the rule of nines with 6 typical clinical fea-
tures of disease intensity (erythema, oedema/papulation, oozing/
crusts, excoriations, lichenification; each assessed on a 4-point Li-
kert scale at a single representative site) plus a 10-cm visual ana-
logue scale for itch and sleep loss due to AE. The SCORAD ranges 
from 0 to 103 with higher scores indicating severer disease  [32] . 
Severe AE was defined as SCORAD  1 50, moderate AE as SCORAD 
20–50. Response was defined as a relative improvement in total 
SCORAD by 50% or more compared to baseline (SCORAD 50). 
Remission was defined as SCORAD  ! 8  [30, 36–38] . SCORAD 
training was attended by all assessors prior to study initiation  [32, 
37] .
 The IGA and PGA are static instruments to assess global dis-
ease severity on a 6-point Likert scale by the physician (IGA) and 
patient (PGA), respectively  [33] . DLQI and Children’s DLQI are 
widely used instruments with adequate psychometric properties 
to measure health-related quality of life in dermatological pa-
tients. The (Children’s) DLQI score ranges from 0 to 30 with high-
er scores (over 10) reflecting worse quality of life  [34, 35, 39, 40] . 
Adverse events were recorded according to the Common Toxicity 
Criteria for Adverse Events, version 3.0  [41] .
 Statistical Analysis 
 The primary end point was the difference in absolute change 
in SCORAD between baseline and mean SCORAD under treat-
ment. We aimed to detect an 8-unit difference between groups. On 
the assumption of a standard deviation of 10 units in both groups, 
calculations showed that 52 participants were needed for a study 
with 80% power and 5% significance (nQuery-Advisor  4.0). We 
aimed to recruit 64 patients to allow for a 20% drop-out rate.
 As secondary end points, we analysed proportions of partici-
pants with remission (SCORAD  ! 8), with response (SCORAD 
50), with significant benefit in quality of life (DLQI change  6 5 
units)  [40] and with a lower global disease severity score as as-
sessed by the physician (IGA) and patient (PGA) at any study vis-
it after baseline and at more than 50% (n = 7) study visits, respec-
tively. For the latter analysis we assumed that a criterion (e.g. re-
sponse) was not met if a participant did not attend a study visit.
 Additionally, we compared the proportions of participants re-
ceiving and the average amount of anti-inflammatory drugs pre-
scribed for AE by drug group, with glucocorticosteroids being 
classified according to Niedner  [42] .
 Primary data analysis was by intention to treat and included 
all randomised participants who attended the baseline visit. In 
the per-protocol analysis (secondary analysis) we included all 
participants who attended at least 80% (n = 12) of all study visits. 
Missing data were not replaced. Proportions were compared us-
ing the   2 test or Fisher’s exact test, continuous variables by t test 
or Mann-Whitney test, as appropriate  [43] . Data were analysed 
with SPSS, version 11.5.1.
 Results 
 Figure 2 shows the trial profile. Sixty-four patients (all 
Caucasians born in Germany) were enrolled and ran-
domly allocated to the algorithm (n = 32) and individual 
groups (n = 32). One patient allocated to individual ther-
apy withdrew before baseline. The following results are 
based on the 63 participants who attended the baseline 
visit ( fig. 2 ). Demographic data and disease characteris-
tics were balanced between groups ( table 1 ). A total of
20 children aged 2–15 years were included in this study, 
10 of whom were allocated to each treatment group.
The mean SCORAD at baseline was 46 units in both 
groups.
 There was no statistically significant difference in 
mean SCORAD change between algorithm and individ-
ual groups. Treatment was highly effective in both groups 
with mean reductions in disease activity of 21.4 SCO-
RAD units (95% confidence interval, CI = 17.6–25.2; i.e. 
47%, 95% CI = 38–55) by algorithm (p  ! 0.001), and 19.3 
SCORAD units (95% CI = 13.6–24.9; 42%, 95% CI = 29–
54) by individual therapy (p  ! 0.001;  table 2 ).
 Figure 3 shows the course of mean (with 95% CI) dis-
ease activity (SCORAD) from baseline over the 1-year 
study period. Compared to baseline, mean disease activ-
ity was significantly lower at all following assessments in 
both groups ( fig. 3 ).
 Clinical response was paralleled with improved qual-
ity of life (DLQI) in both groups. Mean relative improve-
ment in DLQI was 42% (95% CI = 19–66) in patients al-
located to the algorithm group compared to 47% (95%
CI = 27–68) in those allocated to individual therapy. Re-
sults of all secondary outcomes are detailed in  table 2 .
 For all outcome variables, the conclusions to be drawn 
from the per-protocol population ( fig. 2 ) were identical 
with the presented intention-to-treat analysis.
 Significantly more patients allocated to algorithm 
therapy received pimecrolimus (p = 0.002) and tacroli-
mus 0.03% (p  ! 0.001), whereas high-potency corticoste-
roids (class III) were given significantly more often to pa-
tients allocated to individual treatment (p = 0.001;  ta-
ble 3 ). The trend in treatment utilisation was similar in 
children and adults, but differences in treatment utilisa-
tion were less pronounced in children ( tables 3 ,  4 ). De-
spite high baseline severity, phototherapy and systemic 
treatment were rarely administered in both groups ( ta-
ble 3 ).
 A total of 25 violations against the treatment algo-
rithm were documented, with a maximum of 3 viola-
tions per patient. No violations were noted in 14/32 pa-
tients allocated to the algorithm group. This implies that 
physicians adhered to algorithm in 93% of their treat-
ment decisions (348 visits in the algorithm group, 25 al-
gorithm violations). Adherence to the algorithm was 
similar in children (94%) and adults (92%). In all cases of 
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violations, corticosteroids were used instead of calcineu-
rin inhibitors.
 Adverse events were generally mild with common cold 
being the most frequently reported condition. No par-
ticipants developed serious abnormalities in laboratory 
measures. A total of 8 skin infections [verruca vulgaris
(n = 3), tinea (n = 3), folliculitis (n = 1), herpes simplex
(n = 1)] were noted (algorithm n = 5, individual n = 3),
all of which were classified as mild. Six serious adverse 
events were recorded in patients allocated to individual 
therapy [exacerbation of AE (n = 2), corneal infection
(n = 1), appendicitis (n = 1), traumatic rupture of finger 
tendon (n = 1), varicosis surgery (n = 1), each requiring 
hospitalisation] and 1 serious adverse event in patients 
receiving algorithm treatment (renal colic requiring hos-
pitalisation). All serious adverse events were resolved by 
the end of study.
 Discussion 
 This study has two major implications: firstly, it does 
not show any clear advantage of an algorithm-based 
treatment concept for moderate-to-severe AE compared 
to individualised treatment. Secondly, our results dem-
onstrate that disease activity in children and adults with 
moderate-to-severe AE can be effectively controlled when 
applying an evidence-based treatment algorithm that 
considers current disease activity, prior course of disease 
and the patient’s age. Therefore, the concept ‘treatment 
algorithm’ appears to be a possible alternative to the cur-
rent clinical practice of individualised treatment.
 Treatment according to a time- and severity-score-de-
pendent algorithm and individualised treatment were 
both highly effective with mean reductions in disease ac-
tivity over the 12-month study period by 47% in patients 
81 patients screened
17 excluded 
6 did not meet inclusion criteria
11 refused to participate
64 randomised
1 patient withdrew 
before treatment 
(declined treatment)
32 treated by evidence-based 
algorithm and analysed by 
intention to treat
31 received individualised
treatment and analysed by 
intention to treat
32 assigned to 
evidence-based algorithm
32 assigned to 
individualised treatment
7 patients withdrew
4 declined further
study participation
2 did not attend >3 
study visits
1 non-compliance
25 completed treatment by 
evidence-based algorithm 
and analysed per protocol
23 completed individualised
treatment and analysed per 
protocol
8 patients withdrew
4 declined further
study participation
3 non-compliance
1 pregnancy
 Fig. 2. Trial profile. 
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allocated to algorithm therapy and 42% in patients allo-
cated to individual treatment. In both study groups clin-
ical improvements were translated into improved well-
being as indicated by reduced DLQI scores. No statisti-
cally significant differences in clinical or subjective 
response were observed between groups.
 Our study objective was to investigate the effectiveness 
and applicability of the concept ‘evidence-based severity-
score-oriented treatment algorithm’ in the management 
of moderate-to-severe AE. Therefore, it was not our goal 
to develop ‘the best’ algorithm, but a severity-score-ori-
ented and applicable treatment concept that combines the 
evidence of RCTs with the regulatory guidelines (sum-
mary of product characteristics). Due to studies and new 
regulatory guidelines (i.e. FDA black box warning for top-
ical calcineurin inhibitors, January 2006) published after 
the tested algorithm had been developed, the algorithm 
applied in this study needs to be modified before it can be 
recommended for current clinical practice  [44–47] .
 There are at least 3 distinct differences between indi-
vidual symptom-oriented treatment in this trial and man-
agement of moderate-to-severe AE in everyday clinical 
practice, all of which are potential explanations for the 
observed benefit in patients allocated to individual treat-
ment. Firstly, the frequency of medical consultation with 
14 scheduled appointments within 1 year clearly exceeds 
common practice in an outpatient setting. It has been sug-
gested that treatment adherence is higher if patients have 
regular and frequent appointments with their physician 
 [48] . Secondly, physicians in this study regularly applied 
a validated measurement of disease activity and treatment 
success, which is not always the case in clinical practice. 
Additionally, we are not aware of any valid data on the 
exact amount of medications consumed by patients with 
moderate-to-severe AE in clinical practice, but the 
amounts received by our patients are relatively high.
 Surprisingly, both individual response rates and de-
crease in mean disease activity in patients treated by al-
gorithm therapy were similar to the reported efficacy of 
systemic treatment modalities including cyclosporine, 
azathioprine, mycophenolate mofetil and   -interferon  [5, 
7, 49–52] . Baseline severity is frequently inflated in RCTs 
evaluating the efficacy of pharmaceutical interventions 
Table 1. Demographics and clinical characteristics of study par-
ticipants
Time- and
severity-score-
dependent
treatment algo-
rithm (n = 32)
Individualised 
symptom-
oriented 
treatment
(n = 31)
Age, years 24817 21813
Female sex 18 (56) 14 (45)
Allergic rhinoconjunctivitis 19 (59) 21 (68)
Allergic asthma 10 (31) 9 (29)
Raised serum IgE 28 (88) 28 (90)
Previous treatment for atopic eczema
Topical glucocorticosteroids 29 (91) 31 (100)
Topical pimecrolimus 21 (66) 20 (65)
Topical tacrolimus 17 (53) 16 (52)
Phototherapy 10 (31) 12 (39)
Systemic therapy 7 (22) 7 (23)
Hospitalisation 11 (34) 12 (39)
Disease activity (SCORAD) 46812 46819
Body surface area involved, % 41824 35824
Global disease severity assessed by physician (IGA)
Almost clear/mild 7 (23) 7 (23)
Moderate 14 (46) 16 (53)
Severe/very severe 9 (30) 7 (23)
Global disease severity assessed by patient (PGA)1
Almost clear/mild 11 (37) 7 (23)
Moderate 10 (33) 12 (40)
Severe/very severe 9 (30) 11 (37)
Quality of life impact
(Children’s DLQI/DLQI)2 986 1087
Data are means 8 SD or numbers, with percentages in paren-
theses. The Children’s DLQI was used in children 5–16 years old; 
the DLQI was used in patients aged 17 years or older; quality of 
life was not assessed in children aged <5 years. None of the ob-
served differences between groups was statistically significant.
1 n = 30 in each group. 2 n = 26 in each group.
0
10
20
30
40
50
60
D
is
ea
se
 a
ct
iv
it
y 
Time (weeks)Ba
se
lin
e 4 12 20 28 36 44 52
Algorithm (n = 32)
Individual  treatment (n = 31)
 Fig. 3. Disease activity (SCORAD; mean, 95% CI) from baseline 
until 52 weeks of follow-up. 
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Table 2. Effectiveness of treatment according to algorithm and treatment as usual
Time- and severity-score-
dependent treatment 
algorithm (n = 32)
Individualised 
symptom-oriented 
treatment (n = 31)
Mean reduction in disease activity (SCORAD) 21.4 [17.6–25.2] 19.3 [13.6–24.9]
Clinical response (SCORAD 501)
Proportion with response2 31 (97) 27 (87)
Proportion with response at >50% of visits3 14 (44) 11 (35)
Remission (SCORAD <8 units)
Proportion with remission2 9 (28) 11 (35)
Proportion with remission at >50% of visits3 0 0
Global disease severity assessed by physician (IGA)
Proportion with improvement2 31 (97) 30 (97)
Proportion with improvement at >50% of visits3 16 (50) 17 (55)
Global disease severity assessed by patient (PGA)4
Proportion with improvement2 28 (93) 30 (100)
Proportion with improvement at >50% of visits3 17 (57) 17 (57)
Mean improvement in quality of life (DLQI)5 4.0 [1.8–6.2] 4.7 [2.7–6.7]
Quality of life (DLQI)5
Proportion with relevant improvement (≥5 units)2 14 (54) 17 (65)
Proportion with relevant improvement (≥5 units) at >50% of visits3 7 (27) 8 (31)
Data are means, with 95% CI in square brackets, or numbers, with percentages in parentheses. None of the 
observed differences between groups was statistically significant.
1 SCORAD ≤50% of baseline. 2 At any visit after baseline. 3 Based on the assumption that the criterion was 
not met if a study visit was not attended. 4 n = 30 in each group. 5 n = 26 in each group; not assessed in children 
<5 years.
Table 3. Treatment utilisation in patients treated according to evidence-based algorithm compared to treatment 
as usual stratified by age
Total Children (aged 2–15 years) Adults (aged ≥16 years)
algorithm
(n = 32)
individual
(n = 31)
algorithm
(n = 10)
individual
(n = 10)
algorithm
(n = 22)
individual
(n = 21)
Glucocorticosteroids1
Low potency (class I) 15 8 6 4 9 4
Intermediate potency (class II) 28 21 8 9 20 12*
High potency (class III) 14 26** 2 6 12 20**
Calcineurin inhibitors
Pimecrolimus 30 19** 10 8 20 11**
Tacrolimus 0.03% 25 6** 8 4 17 2**
Tacrolimus 0.1% 18 21 1 3 17 18
Phototherapy 3 1 – – 3 1
Prednisolone 1 2 – – 1 2
Cyclosporine 0 1 – – 0 1
Algorithm = Time- and severity-score-dependent treatment algorithm; individual = individualised symp-
tom-oriented treatment. Data are numbers of patients exposed.
* p < 0.05, ** p < 0.01; other differences not statistically significant.
1 Classified according to Niedner [42], very-high-potency (class IV) glucocorticosteroids were not applied 
in both groups.
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for AE by including patients only after a wash-out phase 
for anti-inflammatory drugs  [5, 6] . The fact that there 
was no wash-out phase in our pragmatic RCT under-
scores the effectiveness of the tested algorithm. Despite 
high baseline severity ( table 1 ) only 3 patients allocated to 
the algorithm group required phototherapy, only a single 
patient systemic treatment (prednisolone) and none hos-
pitalisation for AE.
 At least partly because of the design of the algorithm, 
highly potent corticosteroids (class III) and calcineurin 
inhibitors (tacrolimus 0.1%) were applied more frequent-
ly in the individual group and less potent corticosteroids 
(classes I and II) and calcineurin inhibitors (pimecroli-
mus 0.1% and tacrolimus 0.03%) more frequently by algo-
rithm patients. These trends in treatment utilisation were 
qualitatively similar in children and adults, but less pro-
nounced and not statistically significant in children. No-
tably, the use of more potent topical treatments in the 
individual group did not result in better disease control.
 The presented data are not sufficient to adequately 
conduct a cost-effectiveness analysis, but nevertheless 
they allow some conclusions as to the potential health 
economic impact of the algorithm approach. The rela-
tively high amounts of medication consumed in both 
groups should be weighted against presumed savings 
from avoidance of hospitalisation and systemic treat-
ment. Substantial proportions of patients included in this 
study had been hospitalised or treated systemically before 
( table 1 ).
 To closely mirror clinical practice, all patients with 
moderate-to-severe AE were eligible (except those with 
prior malignant disease, pregnancy, breastfeeding or with-
out contraception) without requiring a wash-out phase for 
any drugs administered prior to the study. Participants of 
our study were assessed over a 12-month period. This was 
done to avoid bias by seasonal influences on disease activ-
ity and to test the applicability and effectiveness of a treat-
ment algorithm over a meaningful period of time  [1] .
 Although the SCORAD is a well-validated outcome 
measurement for AE that has been recommended for out-
come assessment in clinical trials and everyday practice, 
it is unknown whether the 8-unit difference we consid-
ered as clinically relevant truly is the correct cut-off  [8] . 
If the clinically relevant difference was truly smaller than 
8 units, our study would have been underpowered to 
show superiority of the algorithm approach.
 Our study suggests that an evidence-based algorithm 
for AE is applicable for children and adults in a dermato-
logical setting: in 93% of study visits in the algorithm 
group, physicians actually applied the treatment suggest-
ed by the algorithm. However, the algorithm was not su-
perior to individual treatment by dermatologists so that 
the algorithm approach might not be needed in a derma-
tological setting. Notably, adequate management of AE 
does not only require effective anti-inflammatory treat-
ment, but also the management of exacerbating factors 
and adjunctive treatment with emollients as well as suf-
ficient patient education and instruction  [1, 9, 19, 36, 53] . 
Table 4. Average amount of drugs (g) utilised by treatment according to evidence-based algorithm compared to treatment as usual 
stratified by age
Total Children (aged 2–15 years) Adults (aged ≥16 years)
algorithm
(n = 32)
individual
(n = 31)
algorithm
(n = 10)
individual
(n = 10)
algorithm
(n = 22)
individual
(n = 21)
Glucocorticosteroids1
Low potency (class I) 36853 16849 37840 36880 36859 7822*
Intermediate potency (class II) 2118328 1058118 1098106 68856 2578383 1128226
High potency (class III) 1108165 2478271* 538129 70892 1368176 3318289**
Calcineurin inhibitors
Pimecrolimus 3468413 1348164** 4028316 1868150 3358458 1108168*
Tacrolimus 0.03% 2348233 15841** 2478282 36866* 2278214 4814**
Tacrolimus 0.1% 1478199 2058272 24876 578106 2038213 2768299
Algorithm = Time- and severity-score-dependent treatment algorithm; individual = individualised symptom-oriented treatment. 
Data are means 8 SD.
* p < 0.05, ** p < 0.01; other differences not statistically significant.
1 Classified according to Niedner [42], very-high-potency (class IV) glucocorticosteroids were not applied in both groups.
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There is increasing evidence that nurse-led clinics for 
children with AE might be an effective and well-accepted 
alternative to conventional care from a doctor  [53] . Fu-
ture studies should explore the acceptability, effective-
ness, efficiency and ease of use of an algorithm-based 
treatment of AE in a large cohort of patients by means of 
a multi-disciplinary study including paediatricians, der-
matologists, general practitioners and nurse-led clinics.
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